Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

  • 250 Accesses

Correction to: Breast Cancer Res

https://doi.org/10.1186/s13058-019-1196-y

After the publication [1] the authors report corrections for Table 3, for the headers of columns 5 and 7, which should read as follows: Column 5 Header: P-value for pCR, T vs Other Arms in HR+, and Column 7 Header: P-value for pCR, T vs Other Arms in HR.

The correct version of the table can be found below:

Table 3 NSABP FB-7: Pathologic complete response (pCR) (breast and nodes) by treatment arm and HR status

Reference

Author information

Correspondence to Samuel A. Jacobs.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jacobs, S.A., Robidoux, A., Abraham, J. et al. Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. Breast Cancer Res 22, 9 (2020). https://doi.org/10.1186/s13058-019-1240-y

Download citation